


IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 18 NO 1 MAR 2001

ISSN 0790-9667



'Arc Reclining' by Vivienne Roche, 1980 (Painted steel sculpture, 15.4 x 48.6 x 23.3cm)
From the Collection at the Irish Museum of Modern Art, Royal Hospital Kilmainham, Dublin 8.
Donated by the Gordon Lambert Trust.

When patients need Ranitidine, save over £10 with Gertac.



By prescribing Gertac you can now save over **35%** on the original brand of Ranitidine.¹ This equates to a substantial **£11.15** saving.²

Gertac contains Ranitidine HCL which has proven efficacy in the treatment of duodenal and gastric ulcers, reflux oesophagitis, Zollinger-Ellison syndrome, and for prophylaxis of duodenal ulcers.

Gertac, available as 150mg and 300mg tablets in convenient patient packs, are the cost effective option.

Gertac
Ranitidine HCL



PRESCRIBING INFORMATION: Presentation: Gertac coated tablets containing Ranitidine Hydrochloride equivalent to 150mg or 300mg Ranitidine. Indications: Treatment of duodenal and gastric ulcers; reflux oesophagitis, Zollinger-Ellison syndrome, and for prophylaxis of duodenal ulcers. Dosage and Administration: Treatment of duodenal and gastric ulcer: 150mg twice a day or 150-300mg after dinner or at bedtime. For duodenal ulcer, the dosage may be increased to 300mg twice a day for up to four weeks. Prophylactic treatment of duodenal ulcer: 150mg after dinner or at bedtime. Reflux oesophagitis: 300mg a day or 150mg twice daily for four to eight weeks or, if necessary, up to twelve weeks. Zollinger-Ellison syndrome: 150mg three or four times a day. The dosage may be increased to 300mg four times a day. Higher doses may be given. Treatment with doses of up to 6g per day have been tolerated. Dosage should be reduced in patients with reduced kidney function. Contra-Indications: Patients who are hypersensitive to any component of the preparation. Ranitidine is contra-indicated in children (below 15 years of age). Patients with a history of acute porphyria should not be treated with Ranitidine. Ranitidine should not be used whilst breast-feeding, as Ranitidine is excreted in breast milk. Warnings and Precautions: Exclude malignancy before therapy for gastric ulcer, or in middle-aged or elderly patients with new or recently changed dyspeptic symptoms. Dosage should be reduced in patients with reduced kidney functions and care should be taken with elderly patients in whom kidney function may be reduced. Use in pregnancy only if essential. An interval of two hours should be left between taking this product and antacids. Side Effects: Headache, dizziness, skin-rash, occasional hepatitis, acute pancreatitis, confusion, depression or hallucinations. Allergic reactions, sometimes as fever or anaphylactic shock. Few cases of reversible blurred vision and as with other H2 antagonists, rare cases of bradycardia and A-V blocks. Cases of gynaecomastia and bone marrow effects. Erythema including rare cases of erythema multiforme, arthralgia or myalgia. Rare cases of agranulocytosis or pancytopenia, sometimes with marrow hyperplasia or aplasia. Leucopenia and thrombocytopenia have occurred in a few patients. Storage Precautions: Store below 25°C in a dry place. Protect from heat and moisture. Package Quantities: 150mg in blister cartons of 60 & 100, 300mg in blister cartons of 30. Legal Category: Prescription Only Medicine. Product Authorisation: PA 57723/1-2. McDermott Laboratories, trading as Gerard Laboratories, 35-36 Baldoye Industrial Estate, Grange Road, Dublin 13. GMS No: Gertac 150mg 60's 27839, Gertac 150mg 100's 27838, Gertac 300mg 30's 27946. Date of Preparation: February 1998. Additional information is available on request from Gerard Laboratories, Sales and Marketing Office, 2004A Orchard Avenue, City West Business Campus, Naas Road, Dublin 24. Freephone 1800-272-272. References: 1. MIMS February 1998. 2. Based on example 150mg BD for 30 days.

Editor-in-Chief: Brian Lawlor

Production Editor:

Anne Henrichsen

Advertising Manager:

Niamh Gleeson

Founding Editor: Mark Hartman

Associate Editors:

Ted Dinan (Cork),
David King (Belfast)

Editorial Board: Ken Brown (Belfast),

Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Brian Leonard (Galway), Roy McClelland (Belfast), Aidan McGennis (Dublin), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), Ethna O'Gorman (Belfast), Brian O'Shea (Wicklow), Ian Pullen (Edinburgh), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Victoria)

Statistical Editor:

Ronan Conroy (Dublin)

Submissions & correspondence to:

The Editor,
Irish Journal of Psychological Medicine,
25 Adelaide Street,
Dun Laoghaire, Co Dublin.

Telephone:

01-2803967; Int: +353-1-2803967

Fax:

01-2807076; Int: +353-1-2807076

Publisher

MedMedia Ltd.
Media House,
25 Adelaide Street,
Dun Laoghaire, Co Dublin.

Printing: New Cityview Press

Subscriptions

Rates per volume of four issues
(Mar, Jun, Sept, Dec)
STG£43 EU, US\$96 USA, STG£53
elsewhere (single issues US\$28 USA,
STG£13.25 elsewhere) incl. airmail
postage internationally.

**Subscription enquiries, orders
and cheques made payable to:**

Royal Society of Medicine Press Ltd.,
1 Wimpole St,
London, W1M 8AE, UK.
Tel: 0171-2902927;
int: +44-171-2902927.
Fax: 0171-2902929;
int: +44-171-2902929.

Circulation

3,000 to 54 countries.
Journal participates in the World Health
Organisation project to improve
distribution of scientific materials on
mental health.
Publication does not imply
endorsement. Limited photocopying
authorisation granted for a fee to
Copyright Clearance Center,
27 Congress Street, Salem, MA 01970,
USA, or to appropriate Reproduction
Rights Organisation; isolated non-profit,
academic photocopying excepted.

EDITORIAL

- 3 **Noradrenaline: the forgotten neurotransmitter**
Christopher B Kelly, Stephen J Cooper

ORIGINAL PAPERS

- 5 **Depression among postnatal women in an urban Irish community**
Elizabeth Cryan, Fiona Keogh, Eibhlin Connolly, Stasia Cody, Ailis Quinlan, Ian Daly
- 11 **Mental health status of homeless children and their families**
AnneMarie Waldron, Genevieve Tobin, Paul McQuaid
- 16 **Medically unexplained symptoms, illness perception and childhood experience in neurology outpatients**
Sarah A Targosz, Navneet Kapur, Francis Creed

BRIEF REPORTS

- 21 **Junior doctors' experience and knowledge of procedures in compulsory psychiatric admissions in Ireland**
Geraldine Swift, M Nasir, John D Sheehan, Patricia R Casey

AUDITS

- 24 **Substance use history taking by trainee psychiatrists: "There is a tide in the affairs of men..."**
Alistair Grandison, Hugh Williams, Adenekan Oyefeso, Luiz Dracteu

REVIEWS

- 27 **Post traumatic stress disorder and the adrenal gland**
John P Tobin

TRAINING

- 29 **The place and purpose of research training for specialist registrars: a view from the Collegiate Trainees' Committee (CTC) of the Royal College of Psychiatrists**
Paul Ramchandani, Catherine Corby, Louise Guest, Alys Cole-King

PERSPECTIVE

- 33 **Suicide, assisted suicide and euthanasia: International perspectives**
Antoon Leenaars, John F Connolly, Chris Cantor, Marlene EchoHawk, Zhao Xiong He, Natalia Kokorina, David Lester, Andrew A Lopatin, Mario Rodriguez, Lourens Schlebusch, Yoshitomo Takahashi, Lakshmi Vijayakumar

23a **John Dunne Medal**

32 **Guidelines for Authors**

38 **Book Reviews**

39 **Letters to the Editor**

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST-PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from **University Microfilms International**, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the **Adonis** service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from **ADONIS BV**, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in **Ulrich's International Periodicals Directory** (**Bowker** International Serials Database), **EBSCO's** Selected Periodicals for the Medical and Health Sciences, & **EBSCO's** Librarians' Handbook.



Fast Response

Can start to improve symptoms of depression within 7 days¹



A first choice antidepressant



Abbreviated Prescribing Information:

LUSTRAL™ (sertraline)
Presentation: Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). Panic disorder, with or without agoraphobia.

Dosage: Lustral should be given as a single daily dose. The initial dose in depression and OCD is 50mg and the usual antidepressant dose is 50mg. The initial dose in panic disorder is 25mg, increasing to 50mg after one week. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose. **Use in children:** Not recommended. **Use in the elderly:** Usual adult dose. **Contra-indications:** Hypersensitivity to this group of drugs. Hepatic insufficiency, unstable epilepsy and convulsant disorders, pregnancy and lactation. Do not use with, or within two weeks of ending treatment with, MAOIs.

starting any MAOI following discontinuation of Lustral. **Precautions, warnings:** Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquillizers in patients who drive or operate machinery. Serotonergic drugs such as tryptophan or fenfluramine should be used with caution. The patient should be monitored for signs of suicide or mania. **Drug Interactions:** Caution with other centrally active medication. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. **Side-Effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating, dizziness, insomnia, somnolence, headache, anorexia and dyspepsia. Rarely, abnormal LFTs, hyponatraemia. The following have been reported with Lustral but may have no causal relationship: vomiting, abdominal pain, movement disorders,

convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea, rash and alopecia. Rarely, pancreatitis, serious liver events, altered platelet function, abnormal bleeding and purpura. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural hypotension, hypo/hypertension, tachycardia and arrhythmias. Withdrawal reactions have been reported with Lustral. Common symptoms include dizziness, paraesthesia, headache, anxiety and nausea. Abrupt discontinuation of treatment with Lustral should be avoided. The majority of symptoms experienced on withdrawal of Lustral are non-serious and self-limiting. **Legal Category:** S1A. **Package Quantities:** 50mg tablet (PA 822/1/4) Calendar pack of 28; 100mg tablet (PA 822/1/5) Calendar pack of 28. **Product Authorisation Holder:** Pfizer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. Further information on request: Pfizer (Ireland) Limited. Date last revised: June 1999. **Reference:** 1. Lapiere YD. *Int Clin Psychopharmacol* 1991; 6 (Suppl. 2): 23-35.



67577 November 99